Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …

It is generally recognized that tumor cells proliferate more rapidly than normal cells. Due to
such an abnormally rapid proliferation rate, cancer cells constantly encounter the limits of …

Cancer immunotherapy is a type of treatment that harnesses the power of the immune
systems of patients to target cancer cells with better precision compared to traditional …

Cancer immunotherapies have yielded promising outcomes in various malignant tumors by
blocking specific immune checkpoint molecules, such as programmed cell death 1 and …

Immunotherapy is a new type of tumor treatment after surgery, radiotherapy and
chemotherapy, and can be used to manage and destroy tumor cells through activating or …

Emerging evidence on molecular biology related to tumors, inflammation, and immunity,
highlights their architectural commonality shifting cancer treatment paradigms toward more …

Cancer is the second leading cause of death worldwide. Traditional approaches, such as
surgery, chemotherapy, and radiotherapy have been the main cancer therapeutic modalities …

The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence
of immune checkpoint inhibitors. However, an objective and durable response rate remains …

We report the generation of a novel anti-LAG-3/TIGIT bispecific IgG4 antibody, ZGGS15, and
evaluated its anti-tumor efficacy in mouse models as monotherapy or in combination with a …